Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Sweet urine, bitter outcome: Empagliflozin and balanoposthitis
Sweet urine, bitter outcome: Empagliflozin and balanoposthitis

We are on our summer break and the editorial office is closed until 13 January. In the meantime, please enjoy our Summer Hiatus series, in which our journalists curate an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading!
This article was first published online on 14 February.
Sexual health specialist Massimo Giola continues his series of short, mostly clinical case-based sexual health articles. This year, he has in mind a mix of transgender medicine and sexology topics, but he starts with a genital dermatology issue he has seen a few times recently
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27(5):479–84.
2. Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014;30(6):1109–19.